Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provides various medicines for allergies; blood circulation and memory; bone and joint; liver and digestive; diabetics; eyes, heart, and skin care; pain, sleeping, well-being, herbal, and cough and colds; and vitamins, probiotics, medical and sports nutrition, as well as kids’, men’s, and women’s care products. The company also offers prescription medicines in the areas of anti-allergic, anti-infective, central nervous system, cardiovascular system, dermatology, diabetes, gastroenterology, gynecology, nephrology, oncology, ophthalmology, orthopedic, pain, respiratory, rheumatology, and urology. In addition, it provides logistical and marketing services for the sale of goods manufactured by third parties, social enterprise, and wellness center, as well as involved in the software design, development, and other services business. The company was incorporated in 1982 and is headquartered in Bangkok, Thailand. Mega Lifesciences Public Company Limited operates as a subsidiary of Unistretch Limited.
Thai Market Performance
7D7 Days: 0.1%
3M3 Months: 1.6%
1Y1 Year: -7.6%
YTDYear to Date: -11.3%
In the last week, the market has been flat. The past year hasn't been profitable, with the market dropping 7.6%. Earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.